Breakthrough Drug Prices Will Be “Huge” Policy Issue; IoM Plans Forum
Executive Summary
The next frontier in the debate over drug pricing will be the cost of highly effective breakthrough drugs, CMS Chief Medical Officer Sean Tunis, MD, predicted during the Biotechnology Industry Organization annual meeting in San Francisco June 7
You may also be interested in...
Gene Therapy’s Roller Coaster Ride
With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.
U.S., Canada, EU See Eye To Eye On Need For Innovation, But What Kind?
The push by global regulatory agencies to stimulate innovation should include consideration of "what kind" of innovation is most needed, European Medicines Evaluation Agency Executive Director Thomas Lonngren said
U.S., Canada, EU See Eye To Eye On Need For Innovation, But What Kind?
The push by global regulatory agencies to stimulate innovation should include consideration of "what kind" of innovation is most needed, European Medicines Evaluation Agency Executive Director Thomas Lonngren said